HC Wainwright & Co. Maintains Buy on Acelyrin, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Acelyrin (NASDAQ:SLRN) but lowers the price target from $28 to $18.

May 09, 2024 | 5:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Acelyrin's price target was reduced from $28 to $18 by HC Wainwright & Co., although the Buy rating was maintained.
The reduction in price target by HC Wainwright & Co. suggests a reassessment of Acelyrin's future financial performance or market position, potentially due to new data or market conditions. However, maintaining a Buy rating indicates a positive outlook on the company's long-term value. This mixed signal could lead to short-term uncertainty among investors, but the maintained Buy rating suggests underlying confidence in the company's fundamentals.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100